Henry Schein (HSIC) drew fresh attention after being dropped from the Russell 1000 Dynamic Index, a change that can reshape index-tracking demand and prompt investors to reassess the stock’s role in diversified portfolios.

At a share price of US$84.29, Henry Schein has seen a 30 day share price return of 10.07% and a 90 day share price return of 15.40%. The 1 year total shareholder return of 13.17% points to steadier long term compounding, even as the recent index removal prompts investors to reassess growth prospects and risk.

If this shift has you thinking about where else capital might work, it could be a good moment to scan for other opportunities through the 41 healthcare AI stocks

With Henry Schein trading at US$84.29, having gained just over 10% over the last 30 days and showing an estimated intrinsic discount of nearly 48%, the key question is straightforward: is this a fresh entry point, or is the market already pricing in future growth?

Most Popular Narrative: 4.3% Undervalued

Based on the most followed narrative, Henry Schein’s fair value of $88.07 sits modestly above the last close of $84.29, framing a mild undervaluation story grounded in detailed forecasts.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments. This supports structurally higher gross margins and is likely to drive earnings expansion. Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention. These initiatives position Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.

Curious what sits behind that fair value gap for Henry Schein? The narrative leans heavily on specific growth, margin and earnings targets that may surprise you.

Result: Fair Value of $88.07 (UNDERVALUED)

However, the Henry Schein narrative can quickly be tested if competitive pricing continues to squeeze distribution margins or if staffing shortages keep dental patient volumes under pressure.

Another View: Henry Schein Through The P/E Lens

There is a catch to the Henry Schein fair value story. On simple P/E, the stock trades at 24.3x, slightly above the peer average of 23.1x and only a touch above the 24.2x fair ratio that our model suggests the market could move toward, which points to limited margin for error.

For investors who lean more on earnings multiples than cash flow models, that narrow gap between the current 24.3x P/E, the 23.1x peer average and the 24.2x fair ratio raises a practical question: is the current price offering enough compensation for execution and competitive risk, or is it closer to a fully demanding entry point, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both optimism and concern around Henry Schein’s outlook, it makes sense to check the underlying data yourself and move promptly. To understand how the positives and negatives balance out, take a closer look at the 2 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Henry Schein?

If you are reassessing Henry Schein, this is also a smart time to widen your watchlist and see what other stocks might better fit your objectives.

• Target potential value opportunities before they are crowded by checking out the 42 high quality undervalued stocks tailored to companies with solid fundamentals.
• Strengthen the quality of your holdings by scanning the solid balance sheet and fundamentals stocks screener (48 results) for businesses that pair financial resilience with sound operations.
• Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems that highlight less-followed stocks with strong underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.